Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Clinical trial NCT06513234 · RECRUITING
Trial details
- NCT number
- NCT06513234
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-11
- Primary completion
- 2026-06-21
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.